Navigation Links
HIKMA - 2008 Preliminary Results Interview With CEO
Date:3/17/2009

LONDON, March 17 /PRNewswire-FirstCall/ -- Hikma Pharmaceuticals today announced strong revenue growth and stable net profits despite a loss at the company's US Generics business. The weakness in the US was offset by a strong performance from the multinational Pharma company's Injectable and Branded businesses. CEO, Said Darwazah, said "The US operations, in 2007, reported operating profit of about $30m and in 2008 we had a loss there so in spite of this $30m plus loss the other divisions, the Branded and the Injectables, performed so well, grew so much that they were able to offset that."

Noting the current macro economic downturn Mr Darwazah said Hikma's diversified business model, both by geography and product, would support growth in 2009. "It's going to be a very, very tough year. And the way we're going to address this, as we said, is by controlled growth. Growth of 10% to 15%."

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE HIKMA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hikma - 2007 Preliminary Results Interviews With CEO and CFO
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
8. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
9. Symmetry Medical Reports Preliminary Third Quarter Revenue
10. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
11. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):